Anonymous: "Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)", ClinicalTrials.gov, 28 August 2017 (2017-08-28), pages 1-8, XP055564774, Retrieved from the Internet: URL:https://www.clinicaltrials.gov/ct2/his tory/NCT02955602?V_21=View#StudyPageTop [retrieved on 2019-03-05] (B1)

Anonymous: "Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)", ClinicalTrials.gov, 30 January 2017 (2017-01-30), pages 1-10, XP055564778, Retrieved from the Internet: URL:https://www.clinicaltrials.gov/ct2/his tory/NCT02609048?V_31=View#StudyPageTop [retrieved on 2019-03-05] (B1)

WO-A1-2015/143178 (B1)

MARINA G. SILVEIRA ET AL: "Investigational drugs in phase II clinical trials for primary biliary cholangitis", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 26, no. 10, 24 August 2017 (2017-08-24), pages 1115-1121, XP055523264, UK ISSN: 1354-3784, DOI: 10.1080/13543784.2017.1371135 (B1)

VINOD S HEGADE ET AL: "A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis", FRONTLINE GASTROENTEROLOGY, vol. 7, no. 3, 26 August 2015 (2015-08-26) , pages 158-166, XP055564100, ISSN: 2041-4137, DOI: 10.1136/flgastro-2015-100618 cited in the application (B1)

D Jones ET AL: "A phase 2 proof of concept study of MBX-8025 in patients with Primary Biliary Cholangitis (PBC) who are inadequate responders to ursodeoxycholic acid (UDCA)", CymaBay Therapeutics, 1 February 2017 (2017-02-01), pages 1-16, XP055564310, Retrieved from the Internet: URL:https://content.equisolve.net/cymabay/ media/2ab054a43f96c6154a9f5ce9f2355a4d.pdf [retrieved on 2019-03-04] (B1)